| Hodgkin Lymphoma
| Non Hodgkin Lymphoma
| Diffuse large B-cell lymphoma
| Intravascular large B-cell lymphoma
| Mantle cell lymphoma
| Marginal Zone Lymphoma
| Gastric (MALT) Lymphoma
| Primary CNS Lymphoma (PCNSL)
| Burkitt's lymphoma
| Follicular Lymphoma
The translocation (11; 14) with subsequent dysregulation of cyclin D1 is a classical feature of this lymphoma.
- Aggressive B-cell non-Hodgkin lymphoma.
- Male to Female 3:1
- There is an overexpression of cyclin
D1 (a protein that stimulates cell growth) in almost
- The overexpression of cyclin D1 is usually
caused by a rearrangement (translocation) between
chromosomes 11 and 14
- Loss of appetite, weight loss, fever, night sweats
- Nausea and/or vomiting, indigestion, abdominal pain or bloating
- Feeling of “fullness” or discomfort from enlarged tonsils
- Liver or spleen, pressure or pain in the lower back that often extends
down one or both legs
- Fatigue from developing anemia
- Lymph nodes, B symptoms, Abdominal swelling
- FBC: Low Hb, Low WCC, low plts or high WCC
- U&E, LFTs, LDH, CRP, ESR
- Measure LDH and Beta2 microglobulin
- CT CAP for staging
- Lymph node biopsy shows cells have surface markers of B cells (e.g., CD20)
- Also overexpress the cyclin D1 protein
- Contain the translocation 11;14.
- First line localised: Consider radiotherapy stage I or II
- First line Advanced Symptomatic disease: Chemotherapy + Rituximab. Consider a cytarabine-containing immunochemotherapy for those fit enough. R-CHOP-based chemotherapy is still a commonly used standard of care
- Bortezomib is recommended for untreated mantle cell lymphoma in adults for whom haematopoietic stem cell transplantation is unsuitable.
- Ibrutinib a Bruton tyrosine kinase (BTK) inhibitor, is approved for patients with
- Autologous stem cell transplantation may be used
to treat MCL in first complete remission.
- NICE are reviewing use of bendamustine for treating people with mantle cell lymphoma,